Management of hallucinations and psychosis in Parkinson's disease

American Journal Geriatric Pharmacotherapy

Volumn 8, Issue 4, 2010, Pages 316-330

  Eng, Marty L ^a   Welty, Timothy E ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

atypical antipsychotics; hallucinations; hallucinosis; neuroleptics; Parkinson's disease; psychosis

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; DELUSION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; HYPERSALIVATION; LOW DRUG DOSE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SOMNOLENCE; SUDDEN DEATH; SYNCOPE; THORAX PAIN; URINARY TRACT INFECTION;

EID: 77957255164     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2010.08.004     Document Type: Review

References (48)

1. S Holroyd, L Currie, and GF Wooten Prospective study of hallucinations and delusions in Parkinson's disease J Neurol Neurosurg Psychiatry 70 2001 734 738
2. D Aarsland, JP Larsen, JL Cummins, and K Laake Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study Arch Neurol. 56 1999 595 601
3. H Meral, T Aydemir, and F Ozer Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease Clin Neurol Neurosurg. 109 2007 862 867
4. S Papapetropoulos, H Katzen, and A Schrag A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease BMC Neurol. 8 2008 21
5. RJ Holt Estimate of point prevalence of Parkinson's disease induced psychosis in the United States Mov Disord. 23 2008 1788 1789
6. D Weintraub, KH Morales, and JE Duda Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease Parkinsonism Relat Disord. 12 2006 427 431
7. S Papapetropoulos, and DC Mash Psychotic symptoms in Parkinson's disease. From description to etiology J Neurol. 252 2005 753 764
8. S Papapetropoulos, AA Argyriou, and J Ellul Factors associated with drug-induced visual hallucinations in Parkinson's disease J Neurol. 252 2005 1223 1228
9. N Giladi, TA Treves, and D Paleacu Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease J Neural Transm. 107 2000 59 71
10. D Ecker, A Unrath, J Kassubek, and M Sabolek Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: A case-control study BMC Neurol. 9 2009 23
11. JS Reijnders, U Ehrt, and R Lousberg The association between motor subtypes and psychopathology in Parkinson's disease Parkinsonism Relat Disord. 15 2009 379 382
12. K Stavitsky, P McNamara, and R Durso Hallucinations, dreaming, and frequent dozing in Parkinson disease: Impact of right-hemisphere neural networks Cogn Behav Neurol. 21 2008 143 149
13. KM Biglan, RG Holloway Jr, MP McDermott, IH Richard Parkinson Study Group CALM-PD Investigators Risk factors for somnolence, edema, and hallucinations in early Parkinson disease Neurology 69 2007 187 195
14. B Ravina, K Marder, and HH Fernandez Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group Mov Disord. 22 2007 1061 1068
15. CG Goetz, S Leuragans, and EJ Papert Prospective longitudinal assessment of hallucinations in Parkinson's disease Neurology 57 2001 2078 2082
16. AD de Maindreville, G Fenelon, and F Mahieux Hallucinations in Parkinson's disease: A follow-up study Mov Disord. 20 2005 212 217
17. CG Goetz, and GT Stebbins Risk factors for nursing home placement in advanced Parkinson's disease Neurology 43 1993 2227 2229
18. CG Goetz, and GT Stebbins Mortality and hallucinations in nursing home patients with advanced Parkinson's disease Neurology 45 1995 669 771
19. D Aarsland, JP Larsen, and JL Cummings Mortality and hallucinations in Parkinson's disease: A four-year longitudinal study J Neuropsychiatry Clin Neurosci 9 1997 642
20. JM Miyasaki, K Shannon, V Voon Quality Standards Subcommittee of the American Academy of Neurology Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 66 2006 996 1002
21. American Academy of Neurology AAN guideline development process http://http://www.aan.com/go/practice/guidelines/development Accessed August 9, 2010
22. Parkinson Study Group Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease N Engl J Med. 340 1999 757 763
23. L Morgante, A Epifanio, and E Spina Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease Neurol Sci. 23 2002 S89 S90
24. A Breier, VK Sutton, and PD Feldman Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease Biol Psychiatry 52 2002 438 445
25. W Ondo, JK Levy, and KD Vuong Olanzapine treatment for dopaminergic-induced hallucinations Mov Disord. 17 2002 1031 1035
26. CG Ballard, M Margallo-Lana, and J Fossey A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments J Clin Psychiatry 62 2001 631 636
27. G Selbaek, O Kirkevold, and K Engecal The course of psychiatric and behavioral symptoms and the use of psychotropic medications in patients with dementia in Norwegian nursing homes-a 12-month follow-up Am J Geriatr Psychiatry 16 2008 528 536
28. JE Overall, and DR Gorham The Brief Psychiatric Rating Scale Psychol Rep. 10 1962 799 812
29. M Berk, F Ng, and S Dodd The validity of the Clinicians Global Impression severity and improvement scales as measures for clinical effectiveness suitable for routine clinical use J Eval Clin Pract. 14 2008 979 983
30. MM Hoehn, and MD Yahr Parkinsonism: Onset, progression, mortality Neurology 17 1967 427 442
31. M Folstein, L Robins, and J Helzer The mini-mental state examination Arch Gen Psychiatry 40 1983 812
32. JL Cummings, M Mega, and K Gray The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia Neurology 44 1994 2308 2314
33. G Freidberg, J Zoldan, and A Weizman Parkinson's Psychosis Rating Scale: A practical instrument for grading psychosis in Parkinson's disease Clin Neuropharmacol. 2 1998 280 284
34. S Leucht, JM Kane, and W Kissling What does the Positive and Negative Symptoms Scale mean? Schizo Res. 79 2005 231 238
35. CG Goetz, BC Tilley, and SR Shaftman Movement Disorders Society-Sponsored revision of Unified Parkinson's Disease Rating Scale: Scale presentation and clinimetric testing results Mov Disord. 23 2008 2129 2170
36. P Pollak, F Tison, and O Rascol Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up J Neurol Neurosurg Psychiatry 75 2004 689 695
37. HH Fernandez, EM Donnelly, and JH Friedman Long-term outcome of clozapine use for psychosis in parkinsonian patients Mov Disord. 19 2004 831 833
38. L Gomide, A Kummer, F Cardoso, and AL Teixeira Use of clozapine in Brazilian patients with Parkinson's disease Arq Neuropsiquiatr 66 2008 611 614
39. F Mancini, C Tassorelli, and E Martignoni Longterm evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease Clin Neuropharmacol. 27 2004 33 37
40. JL Juncos, VJ Roberts, and ML Evatt Quetiapine improves psychotic symptoms and cognition in Parkinson's disease Mov Disord. 19 2004 29 35
41. WG Ondo, R Tintner, and KD Voung Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease Mov Disord. 20 2005 958 963
42. T Prohorov, C Klein, and A Miniovitz The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview J Neurol. 253 2006 171 175
43. C Klein, T Prokhorov, and A Miniovich Long-term follow-up (24 months) of quetiapine treatment in druginduced Parkinson disease psychosis Clin Neuropharmacol. 29 2006 215 219
44. JM Rabey, T Prokhorov, and A Miniovitz Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration Mov Disord. 22 2007 313 318
45. R Kurlan, J Cummings, R Raman, L Thal Alzheimer's Disease Cooperative Study Group Quetiapine for agitation or psychosis in patients with dementia and parkinsonism Neurology 68 2007 1356 1363
46. L Morgante, A Epifanio, and E Spina Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis Clin Neuropharmacol. 27 2004 153 156 [published correction appears in Clin Neuropharmacol. 2004;27:256]
47. D Merims, M Balas, and C Peretz Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson's disease psychosis Clin Neuropharmacol. 29 2006 331 337
48. CG Goetz, W Fan, and S Leurgans Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening Mov Disord 23 2008 1541 1545